Zacks Investment Research upgraded shares of BTG (NASDAQ:BTGGF) from a hold rating to a buy rating in a research note released on Monday. Zacks Investment Research currently has $10.00 price target on the stock.

According to Zacks, “BTG plc is a healthcare company. Its operating segment consists of Interventional Medicine and Specialty Pharmaceuticals. Interventional Medicine offers treatment of cancer, severe emphysema, severe blood clots and varicoseveins. Specialty Pharmaceuticals helps patients overexposed to certain medications or toxins. BTG plc is headquartered in London, the United Kingdom. “

BTG (NASDAQ:BTGGF) traded down 0.87% during trading on Monday, reaching $9.15. 9,500 shares of the company’s stock were exchanged. The company’s 50 day moving average price is $8.90 and its 200-day moving average price is $8.49. The stock has a market capitalization of $3.52 billion and a price-to-earnings ratio of 80.97. BTG has a 52 week low of $6.74 and a 52 week high of $9.35.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at

Get a free copy of the Zacks research report on BTG (BTGGF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related stocks with our FREE daily email newsletter.